BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

923 related articles for article (PubMed ID: 26155316)

  • 1. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
    Durymanov MO; Rosenkranz AA; Sobolev AS
    Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting toxicity and efficacy of polymeric nanomedicines.
    Igarashi E
    Toxicol Appl Pharmacol; 2008 May; 229(1):121-34. PubMed ID: 18355886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging-assisted anticancer nanotherapy.
    Dasgupta A; Biancacci I; Kiessling F; Lammers T
    Theranostics; 2020; 10(3):956-967. PubMed ID: 31938045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extravasation of polymeric nanomedicines across tumor vasculature.
    Danquah MK; Zhang XA; Mahato RI
    Adv Drug Deliv Rev; 2011 Jul; 63(8):623-39. PubMed ID: 21144874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicines for the treatment of hematological malignancies.
    Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
    J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermia approaches for enhanced delivery of nanomedicines to solid tumors.
    Frazier N; Ghandehari H
    Biotechnol Bioeng; 2015 Oct; 112(10):1967-83. PubMed ID: 25995079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment.
    Jain V; Jain S; Mahajan SC
    Curr Drug Deliv; 2015; 12(2):177-91. PubMed ID: 25146439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery.
    Zhang B; Hu Y; Pang Z
    Front Pharmacol; 2017; 8():952. PubMed ID: 29311946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors.
    Danhier F; Danhier P; De Saedeleer CJ; Fruytier AC; Schleich N; des Rieux A; Sonveaux P; Gallez B; Préat V
    Int J Pharm; 2015 Feb; 479(2):399-407. PubMed ID: 25578367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
    Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
    Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
    Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
    Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.
    Gao N; Bozeman EN; Qian W; Wang L; Chen H; Lipowska M; Staley CA; Wang YA; Mao H; Yang L
    Theranostics; 2017; 7(6):1689-1704. PubMed ID: 28529645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
    Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
    AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing Tumor Penetration of Nanomedicines.
    Sun Q; Ojha T; Kiessling F; Lammers T; Shi Y
    Biomacromolecules; 2017 May; 18(5):1449-1459. PubMed ID: 28328191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy.
    Qin M; Xia H; Xu W; Chen B; Wang Y
    Adv Drug Deliv Rev; 2023 Dec; 203():115137. PubMed ID: 37949414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The development of novel tumor targeting delivery strategy].
    Gao HL; Jiang XG
    Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
    van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
    Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of biophysical properties of tumor extracellular matrix on intratumoral fate of nanoparticles: Implications on the design of nanomedicine.
    Tian Y; Cheng T; Sun F; Zhou Y; Yuan C; Guo Z; Wang Z
    Adv Colloid Interface Sci; 2024 Apr; 326():103124. PubMed ID: 38461766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.